Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of gu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Oddo, Daniele, Sennott, Erin M., Barault, Ludovic, Valtorta, Emanuele, Arena, Sabrina, Cassingena, Andrea, Filiciotto, Genny, Marzolla, Giulia, Elez, Elena, van Geel, Robin M.J.M., Bartolini, Alice, Crisafulli, Giovanni, Boscaro, Valentina, Godfrey, Jason T., Buscarino, Michela, Cancelliere, Carlotta, Linnebacher, Michael, Corti, Giorgio, Truini, Mauro, Siravegna, Giulia, Grasselli, Julieta, Gallicchio, Margherita, Bernards, René, Schellens, Jan H.M., Tabernero, Josep, Engelman, Jeffrey A., Sartore-Bianchi, Andrea, Bardelli, Alberto, Siena, Salvatore, Corcoran, Ryan B., Di Nicolantonio, Federica
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970882/
https://ncbi.nlm.nih.gov/pubmed/27312529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0396
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak